Treatment of multiple sclerosis: role of natalizumab
Author:
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s10072-009-0147-2.pdf
Reference40 articles.
1. The IFNB MS Study Group (1993) Interferon beta 1B is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661
2. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular Interferon beta 1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294
3. PRISMS (Prevention of Relapses and Disability by Interferon B-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498–1504
4. Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of the phase III multicenter, double blind, placebo-controlled trial. Neurology 45:1269–1276
5. Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy;Multiple Sclerosis Journal;2021-04-15
2. Growth Hormone (GH) and Cardiovascular System;International Journal of Molecular Sciences;2018-01-18
3. Corrigendum to ‘Multiple sclerosis: New insights and trends’;Asian Pacific Journal of Tropical Biomedicine;2017-05
4. iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles;Frontiers in Immunology;2016-11-30
5. Multiple sclerosis: New insights and trends;Asian Pacific Journal of Tropical Biomedicine;2016-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3